[{"id":"17de40db-c7f4-4c4a-854e-574167dd0b13","acronym":"APEAK","url":"https://clinicaltrials.gov/study/NCT06947811","created_at":"2025-06-07T14:40:16.432Z","updated_at":"2025-06-07T14:40:16.432Z","phase":"Phase 1/2","brief_title":"A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations","source_id_and_acronym":"NCT06947811 - APEAK","lead_sponsor":"Sun Yat-sen University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 06/09/2025","start_date":" 06/09/2025","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-06-04"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"2f190dc6-00a3-45d6-9b51-b88bbf396147","acronym":"ACHIEVE","url":"https://clinicaltrials.gov/study/NCT04808752","created_at":"2021-03-23T07:14:21.731Z","updated_at":"2024-07-02T16:35:08.479Z","phase":"Phase 2","brief_title":"Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases","source_id_and_acronym":"NCT04808752 - ACHIEVE","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/09/2021","start_date":" 07/09/2021","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2024-04-22"},{"id":"9b651402-0977-4060-9673-b32ace371339","acronym":"LungMate-007","url":"https://clinicaltrials.gov/study/NCT04685070","created_at":"2021-01-19T20:47:26.429Z","updated_at":"2024-07-02T16:35:12.523Z","phase":"Phase 2","brief_title":"Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04685070 - LungMate-007","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-27"},{"id":"db20d633-2c0b-4c48-84b0-ae317966a325","acronym":"","url":"https://clinicaltrials.gov/study/NCT05946460","created_at":"2023-07-14T18:09:07.375Z","updated_at":"2024-07-02T16:35:20.833Z","phase":"Phase 2","brief_title":"Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.","source_id_and_acronym":"NCT05946460","lead_sponsor":"The First Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 07/10/2025","primary_completion_date":" 07/10/2025","study_txt":" Completion: 07/10/2025","study_completion_date":" 07/10/2025","last_update_posted":"2024-02-06"},{"id":"d6a118c2-8cf3-4103-9203-82d15917f3c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06185400","created_at":"2023-12-29T18:18:16.940Z","updated_at":"2024-07-02T16:35:24.913Z","phase":"Phase 2","brief_title":"RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations","source_id_and_acronym":"NCT06185400","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Irene (pyrotinib) • Ameile (aumolertinib) • Aidixi (disitamab vedotin) • Ivesa (firmonertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-12-29"},{"id":"7d41bb5c-8775-4bbb-9bda-315d6ca7d0d0","acronym":"SELECT-2","url":"https://clinicaltrials.gov/study/NCT04401059","created_at":"2023-12-27T18:16:50.631Z","updated_at":"2024-07-02T16:35:25.073Z","phase":"Phase 4","brief_title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","source_id_and_acronym":"NCT04401059 - SELECT-2","lead_sponsor":"Tian Xie","biomarkers":" EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR positive","tags":["EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 744","initiation":"Initiation: 11/09/2020","start_date":" 11/09/2020","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2023-12-27"},{"id":"d0409497-b75d-44b0-85df-4030915dc145","acronym":"HS-10241-301","url":"https://clinicaltrials.gov/study/NCT06110663","created_at":"2023-11-01T15:12:24.088Z","updated_at":"2024-07-02T16:35:30.877Z","phase":"Phase 3","brief_title":"A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy","source_id_and_acronym":"NCT06110663 - HS-10241-301","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M • MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Ameile (aumolertinib) • dalmelitinib (HS-10241)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/30/2023","start_date":" 12/30/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2023-11-01"},{"id":"6f742877-39f1-45fb-91cd-0b77705ead8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06102928","created_at":"2023-10-26T15:14:21.989Z","updated_at":"2024-07-02T16:35:31.601Z","phase":"","brief_title":"A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation","source_id_and_acronym":"NCT06102928","lead_sponsor":"Kunming Medical University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2023-10-26"},{"id":"abcd5270-c32a-4e5e-9f9c-f76866979d8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043973","created_at":"2023-09-21T15:10:34.200Z","updated_at":"2024-07-02T16:35:36.485Z","phase":"Phase 3","brief_title":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance","source_id_and_acronym":"NCT06043973","lead_sponsor":"Qianfoshan Hospital","biomarkers":" EGFR • TP53","pipe":" | ","alterations":" TP53 mutation • EGFR mutation","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2023-09-21"},{"id":"7be53d07-7de5-4adc-8258-414ec0f6d703","acronym":"","url":"https://clinicaltrials.gov/study/NCT05994339","created_at":"2023-08-16T16:08:18.339Z","updated_at":"2024-07-02T16:35:38.802Z","phase":"Phase 2/3","brief_title":"Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer","source_id_and_acronym":"NCT05994339","lead_sponsor":"Laibin People's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 08/08/2025","primary_completion_date":" 08/08/2025","study_txt":" Completion: 12/08/2025","study_completion_date":" 12/08/2025","last_update_posted":"2023-08-29"},{"id":"390444f1-9c97-4bec-92b0-570215732181","acronym":"","url":"https://clinicaltrials.gov/study/NCT05826483","created_at":"2023-04-24T14:04:01.324Z","updated_at":"2024-07-02T16:35:49.856Z","phase":"Phase 1","brief_title":"Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status","source_id_and_acronym":"NCT05826483","lead_sponsor":"Guangzhou Institute of Respiratory Disease","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/28/2024","primary_completion_date":" 12/28/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-04-24"},{"id":"0736c99b-5a60-485b-9591-4fe5b2ba0159","acronym":"","url":"https://clinicaltrials.gov/study/NCT05810350","created_at":"2023-04-12T14:03:28.669Z","updated_at":"2024-07-02T16:35:50.642Z","phase":"Phase 2","brief_title":"Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles","source_id_and_acronym":"NCT05810350","lead_sponsor":"Three Gorges Hospital of Chongqing University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-04-13"},{"id":"6f61d3e1-da21-491a-90da-f855c57111f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800223","created_at":"2023-04-05T14:03:37.911Z","updated_at":"2024-07-02T16:35:51.369Z","phase":"Phase 3","brief_title":"Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05800223","lead_sponsor":"Shanghai Cancer Hospital, China","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-04-05"},{"id":"e37bd027-a61d-4c02-b3c0-77dfb443d7c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05778149","created_at":"2023-03-21T14:03:10.775Z","updated_at":"2024-07-02T16:35:52.792Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation","source_id_and_acronym":"NCT05778149","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR • TP53","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Ameile (aumolertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2023-03-21"},{"id":"df533880-a4f7-4004-b024-27678e967b90","acronym":"","url":"https://clinicaltrials.gov/study/NCT04519983","created_at":"2021-01-18T21:39:37.462Z","updated_at":"2024-07-02T16:35:53.011Z","phase":"Phase 2","brief_title":"Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs","source_id_and_acronym":"NCT04519983","lead_sponsor":"Shanghai Cancer Hospital, China","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2023-03-20"},{"id":"497a1906-a32d-426b-a544-ecea08a4976a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05754736","created_at":"2023-03-06T15:01:32.562Z","updated_at":"2025-02-25T16:27:15.589Z","phase":"Phase 2","brief_title":"Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.","source_id_and_acronym":"NCT05754736","lead_sponsor":"The Second Affiliated Hospital of Shandong First Medical University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-03-06"},{"id":"a44fd9da-48a5-4030-9451-0e84dbc43d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05430386","created_at":"2022-06-24T15:56:28.883Z","updated_at":"2024-07-02T16:35:55.559Z","phase":"Phase 1","brief_title":"Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05430386","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib) • dalmelitinib (HS-10241)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-14"},{"id":"4b3212dc-94b8-4477-92db-c1211e26a2ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05534113","created_at":"2022-09-09T15:55:06.526Z","updated_at":"2024-07-02T16:36:03.944Z","phase":"Phase 2","brief_title":"Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC","source_id_and_acronym":"NCT05534113","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib) • Enweida (envafolimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-09-14"},{"id":"a4c03fef-c40c-4187-8982-a08d4d9d7693","acronym":"MWA","url":"https://clinicaltrials.gov/study/NCT04755738","created_at":"2021-02-16T12:53:44.445Z","updated_at":"2024-07-02T16:36:24.808Z","phase":"Phase 2","brief_title":"Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04755738 - MWA","lead_sponsor":"Qianfoshan Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2021-09-06"},{"id":"512c4eef-d88e-46b7-945c-8453e7a1b4d5","acronym":"ARTISTRY","url":"https://clinicaltrials.gov/study/NCT04778800","created_at":"2021-03-23T07:14:18.351Z","updated_at":"2024-07-02T16:36:25.087Z","phase":"","brief_title":"A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)","source_id_and_acronym":"NCT04778800 - ARTISTRY","lead_sponsor":"Henan Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/20/2021","start_date":" 03/20/2021","primary_txt":" Primary completion: 02/20/2023","primary_completion_date":" 02/20/2023","study_txt":" Completion: 02/20/2024","study_completion_date":" 02/20/2024","last_update_posted":"2021-08-31"},{"id":"05b6e938-73e7-4897-8be2-468d1aceb708","acronym":"GASTO 1063","url":"https://clinicaltrials.gov/study/NCT04978753","created_at":"2021-07-27T15:52:58.178Z","updated_at":"2024-07-02T16:36:27.416Z","phase":"Phase 2","brief_title":"the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04978753 - GASTO 1063","lead_sponsor":"Li-kun Chen","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 05/30/2022","primary_completion_date":" 05/30/2022","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2021-07-27"},{"id":"82fdb592-a1ad-41c7-b380-5a89cceb0efb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04951648","created_at":"2021-07-07T13:54:05.052Z","updated_at":"2024-07-02T16:36:28.248Z","phase":"Phase 3","brief_title":"A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation","source_id_and_acronym":"NCT04951648","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Ameile (aumolertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 10/04/2023","primary_completion_date":" 10/04/2023","study_txt":" Completion: 09/06/2024","study_completion_date":" 09/06/2024","last_update_posted":"2021-07-07"}]